The Ins and Outs of Endocytosis inhibition: Providing diverse opportunities for treatment of incurable cancers

内吞作用抑制的来龙去脉：为治疗无法治愈的癌症提供多种机会

• 批准号: nhmrc : 2001396
• 金额: $ 91.24万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/the-ins-outs-incurable-cancers/1779777
• 关键词: Ins; Outs; Endocytosis; inhibition; Providing

The best new immune system anti-cancer drugs only work in ~30% of patients. We found a way to move the drug targets around in people's tumours temporarily to reverse resistance and have tested this in clinical trials. Here we propose to use immunology and the world's frontier electron microscope techniques to work out exactly what is happens to the tumours, immune cells and anti-cancer drugs when they interact in real clinical situations. The aim is to reach at least 60% patient response rate.

最好的新型免疫系统抗癌药物只对~30%的患者有效。我们找到了一种方法，可以在人们的肿瘤中暂时移动药物靶点，以逆转耐药性，并在临床试验中进行了测试。在这里，我们建议使用免疫学和世界前沿的电子显微镜技术来研究肿瘤、免疫细胞和抗癌药物在实际临床情况下相互作用时究竟发生了什么。目标是达到至少60%的患者反应率。